

## Vicore to Present at Upcoming Investor Conferences

**Stockholm, August 28, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following conferences:**

- **Cantor Global Healthcare Conference 2025**  
**Location:** New York, USA  
**Format:** Fireside chat and 1x1 meetings  
**Presentation Date and Time:** Wednesday, September 3 at 1:00 PM ET  
**Webcast:** [Registration](#)  
**Participants:** Ahmed Mousa, CEO
- **Wells Fargo Healthcare Conference 2025**  
**Location:** Boston, USA  
**Format:** Fireside chat and 1x1 meetings  
**Presentation Date and Time:** Friday, September 5 at 12:00 PM ET  
**Webcast:** [Registration](#)  
**Participants:** Ahmed Mousa, CEO, and Megan Richards, VP of IR
- **Morgan Stanley Global Healthcare Conference 2025**  
**Location:** New York, USA  
**Format:** Fireside chat and 1x1 meetings  
**Presentation Date and Time:** Monday, September 8 at 10:00 AM ET  
**Webcast:** [Registration](#)  
**Participants:** Ahmed Mousa, CEO, and Megan Richards, VP of IR

The company's management team will also be available for meetings at the conferences. Interested parties may access the webcast replay on the [Events & Presentations](#) page of Vicore's website for 90 days following the conclusion of the event.

**For further information, please contact:**

Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [megan.richards@vicorepharma.com](mailto:megan.richards@vicorepharma.com)

Hans Jeppsson, CFO, tel: +46 70 553 14 65, [hans.jeppsson@vicorepharma.com](mailto:hans.jeppsson@vicorepharma.com)

**About Vicore Pharma**

*Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.*

*The company's shares are listed on Nasdaq Stockholm's main market (VICO). [www.vicorepharma.com](http://www.vicorepharma.com)*

**Attachments**

[Vicore to Present at Upcoming Investor Conferences](#)